CA2662012C - Boris isoforms and methods of detecting and treating disease - Google Patents

Boris isoforms and methods of detecting and treating disease Download PDF

Info

Publication number
CA2662012C
CA2662012C CA2662012A CA2662012A CA2662012C CA 2662012 C CA2662012 C CA 2662012C CA 2662012 A CA2662012 A CA 2662012A CA 2662012 A CA2662012 A CA 2662012A CA 2662012 C CA2662012 C CA 2662012C
Authority
CA
Canada
Prior art keywords
boris
expression
isoform
seq
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2662012A
Other languages
English (en)
French (fr)
Other versions
CA2662012A1 (en
Inventor
Victor V. Lobanenkov
Elena Pugacheva
Dmitri Loukinov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of CA2662012A1 publication Critical patent/CA2662012A1/en
Application granted granted Critical
Publication of CA2662012C publication Critical patent/CA2662012C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2662012A 2006-08-31 2007-08-30 Boris isoforms and methods of detecting and treating disease Active CA2662012C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84134206P 2006-08-31 2006-08-31
US60/841,342 2006-08-31
PCT/US2007/077281 WO2008028066A2 (en) 2006-08-31 2007-08-30 Boris isoforms and methods of detecting and treating disease

Publications (2)

Publication Number Publication Date
CA2662012A1 CA2662012A1 (en) 2008-03-06
CA2662012C true CA2662012C (en) 2018-06-19

Family

ID=38846916

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2662012A Active CA2662012C (en) 2006-08-31 2007-08-30 Boris isoforms and methods of detecting and treating disease

Country Status (6)

Country Link
US (2) US8206933B2 (enExample)
EP (1) EP2057469A2 (enExample)
JP (1) JP2010502192A (enExample)
AU (1) AU2007289149B2 (enExample)
CA (1) CA2662012C (enExample)
WO (1) WO2008028066A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7998486B2 (en) * 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
WO2009035804A2 (en) * 2007-08-10 2009-03-19 Oncomune, Llc Gene silencing of the brother of the regulator of imprinted sites (boris)
CA2962558C (en) * 2014-09-24 2023-12-12 Sapporo Medical University A brother of the regulator of imprinted sites (boris)-derived tumor antigen peptide
US10415094B2 (en) 2016-10-06 2019-09-17 HelicalHelp LLC Risk stratification method for a patient having a polymorphism
MX2021008808A (es) 2019-01-24 2021-08-24 Lumus Ltd Sistemas opticos que incluyen loe con expansion de tres etapas.
US12487457B2 (en) 2020-06-01 2025-12-02 Lumus Ltd. Virtual image delivery system for near eye displays
TW202538365A (zh) 2020-08-23 2025-10-01 以色列商魯姆斯有限公司 光學系統

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375206B2 (en) * 2002-02-22 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Brother of the regulator of imprinted sites (BORIS)
EP1802972B1 (en) * 2004-09-21 2009-05-27 Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Method of detecting cancer based on immune reaction to boris

Also Published As

Publication number Publication date
WO2008028066A3 (en) 2008-05-08
CA2662012A1 (en) 2008-03-06
AU2007289149B2 (en) 2013-08-15
WO2008028066A2 (en) 2008-03-06
WO2008028066A8 (en) 2009-08-06
AU2007289149A1 (en) 2008-03-06
US20120237520A1 (en) 2012-09-20
US8206933B2 (en) 2012-06-26
JP2010502192A (ja) 2010-01-28
US20100021465A1 (en) 2010-01-28
US8440415B2 (en) 2013-05-14
EP2057469A2 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
US20200326344A1 (en) Soluble B7-H1
US10705089B2 (en) Methods and kits for the diagnosis of cancer
EP2156184B1 (en) Methods for diagnosing and treating prostate and lung cancer
US8440415B2 (en) BORIS isoforms and methods of detecting and treating disease
US8415107B2 (en) Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer
KR20120041175A (ko) 미량 존재하는 인간 혈장 단백질 바이오마커의 신규 패널을 이용한 간성 섬유증의 임상적 진단
CN108496083A (zh) 用于检测包含组蛋白修饰和变体的核小体的方法
US20090258358A1 (en) Methods for Diagnosing and Treating Kidney and Colorectal Cancer
Murphy et al. Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays
KR20130081952A (ko) 암 진단용 바이오마커 및 이를 이용한 암세포 분리 방법
WO2011116209A2 (en) Using phage epitopes to profile the immune response
KR20080046693A (ko) 요로상피암의 검출용 키트 및 방법
US7785814B2 (en) Method of detecting cancer based on immune reaction to BORIS
JP2014115186A (ja) 胃癌、肺癌及び／又は食道癌の検出方法
KR101901457B1 (ko) 간암 암 줄기세포 특성에 기초한 간암의 신규 바이오마커 및 그의 용도
EP2650307A1 (en) IMMUNOLOGICAL cofilin-1 PROTEIN MEASUREMENT METHOD
WO2003020115A2 (en) Methods and compositions for the detection of cancer
JP2014115188A (ja) 胃癌、膵癌、肺癌及び／又は食道癌の検出方法
HK1169168A1 (zh) 作为癌症的标记物的dppiv/seprase的用途
HK1169168B (en) Use of dppiv/seprase as a marker for cancer
WO2012024643A2 (en) MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY

Legal Events

Date Code Title Description
EEER Examination request